Lung cancer risk and the inhibitors of angiotensinconverting enzyme: A mini-review of recent evidence

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) are among the most widely prescribed antihypertensive medications. They are indicated in the management of multiple chronic conditions including hypertension, diabetes mellitus and heart failure. ACEIs prevent angiotensin II (Ang II) production and bradykinin catabolism leading to vasodilation and reduction of arterial blood pressure. Recently, the role of the reninangiotensin system (RAS) inhibitors has become the subject of scrutiny in the treatment of cancer metastasis. The administration of ACEIs, however, has been described to be accompanying with carcinogenic effects.

ACE I/D polymorphism is not a genetic modifier of renal features in sickle cell anemia patients

“…ACEIs are safe and effective in providing cardio-renal protection by decreasing albuminuria in SCA patients (36). However, ACEIs have been linked to some side effects, including a dry, irritating cough and a higher risk of lung cancer (37).…”

An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?

“…The MERS-CoV was known for the first time in Saudi Arabia in 2012 and resulted in 2,494 definite cases of infection and 858 deaths since September 2012 [ 15 – 17 ]. The receptor which SARS-CoV utilizes for contaminating type II pneumocytes and ciliated bronchial epithelial cells is angiotensin-converting enzyme 2 (ACE2) [ 18 – 20 ], while MERS- CoV employs dipeptidyl peptidase 4 [ 21 ] (DPP4) receptor and contaminates type II pneumocytes and unciliated bronchial epithelial cells [ 22 – 24 ]. SARS-CoV and MERS-CoV were spread to individuals from market civets and camels, respectively, and both of them are suspected of originating in bats [ 25 – 31 ].…”